Table 2.
Metabolic syndrome components in LT recipients versus matched NHANES controls
| LT (n=83) |
NHANES controls (n=235) |
OR for LT, unadjusted* (95% CI) |
p | OR for LT,* adjusted for overweight/obesity and glucocorticoids (95% CI) |
p | |
|---|---|---|---|---|---|---|
| Weight status by BMI/BMI %ile | ||||||
| Overweight | 18% | 24% | 0.48 (0.27–0.85)** | 0.01 | – | – |
| Obese | 8% | 19% | ||||
| Elevated waist circumference | 16% | 27% | 0.51 (0.27–0.99) | 0.05 | – | – |
| Systolic pre-hypertension or hypertension | 24% | 12% | 2.51 (1.25–5.04) | 0.01 | 2.94 (1.31–6.61)† | 0.009 |
| Diastolic pre-hypertension or hypertension | 12% | 5% | 2.71 (1.15–6.57) | 0.03 | 4.84 (1.49 – 15.63)† | 0.008 |
| Elevated fasting glucose (≥100mg/dL) | 19% | 19% | 0.93 (0.48–1.78) | 0.83 | 1.09 (0.55–2.18)† | 0.79 |
| IGT (2-hour glucose ≥ 140mg/dL) § | 30% | 6% | 6.70 (3.07–14.59) | <0.001 | 6.50 (2.76 – 15.30) | <0.001 |
| Low HDL | 38% | 24% | 1.79 (1.06–3.06) | 0.03 | 2.86 (1.50–5.44)† | 0.001 |
| Elevated triglycerides | 13% | 22% | 0.53 (0.26–1.07) | 0.08 | 0.56 (0.27–1.19)† | 0.13 |
| Elevated LDL | 2% | 14% | 0.17 (0.04–0.71) | 0.02 | 0.08 (0.01–0.64)† ‡ | 0.02 |
| Elevated total cholesterol | 2% | 22% | 0.09 (0.02–0.37) | 0.001 | 0.04 (0.01–0.33)‡ | 0.002 |
| Metabolic syndrome | 14% | 14% | 0.96 (0.46–2.01) | 0.93 | 1.69 (0.56–5.10)† | 0.35 |
*
ORs calculated using conditional fixed-effects logistic regression with adjustment for confounders as noted.
**
OR for overweight/obesity prevalence in LT compared to NHANES controls.
†
Overweight/obesity is also a statistically significant risk factor in conditional regression (data not shown).
‡
Steroid use is also a statistically significant risk factor in conditional regression (data not shown).
¶
Unable to calculate. All 3 controls with diastolic hypertension were overweight/obese. 1 of 3 LT recipients with diastolic hypertension was overweight/obese.
§
76 LT recipients had 2-hour glucose.